Ignite Creation Date:
2024-05-06 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03672539
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2018-09-10
Brief Title:
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia AML or High Risk Myelodysplastic Syndrome
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory Acute Myeloid Leukemia |
| Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
| Chronic Myelomonocytic Leukemia |
| High Risk Myelodysplastic Syndrome |
| Myelodysplastic Syndrome |
| Recurrent Acute Myeloid Leukemia |
Keywords: